title: Acute effects of sigma ligands on the extracellular DOPAC level in rat frontal cortex and striatum.
abstract: Acute administration of (+)-N-allylnormetazocine ((+)-SKF-10,047) and (+/-)-pentazocine, was found to increase the extracellular level of 3,4-dihydroxyphenylacetic acid (DOPAC), a major dopamine (DA) metabolite, in the rat frontal cortex. By contrast, these benzomorphan sigma ligands did not change the extracellular DOPAC level in the rat striatum. On the other hand, 1,3-di(2-tolyl)guanidine (DTG) increased the extracellular DOPAC level in the frontal cortex, while it decreased that level in the striatum. Another non-benzomorphan sigma ligand, (+)-3-(3-hydroxyphenyl)-N-(1-propyl)piperidine ((+)-3-PPP) decreased the extracellular DOPAC level in both frontal cortex and striatum. Moreover, the increase of the extracellular DOPAC level elicited by (+)-SKF-10,047 was significantly inhibited by rimcazole, a putative sigma antagonist, while the DTG-induced increment was not reversed by rimcazole. These findings indicated that the effects of sigma ligands on the mesocortical DA neurons differed from those on the nigrostriatal DA neurons. In addition, the effects of benzomorphan sigma ligands on the central DA neurons were different from those of non-benzomorphan sigma ligands.
authors.affiliation: Central Research Laboratories, Santen Pharmaceutical Co., Ltd., Osaka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Matsuno
authors.forename: K H
authors.initials: KH
authors.lastname: Matsunaga
authors.forename: S
authors.initials: S
authors.lastname: Mita
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism*; D000818:Animals; D000927:Anticonvulsants / Q000494:pharmacology; D014150:Antipsychotic Agents / Q000494:pharmacology; D002227:Carbazoles / Q000494:pharmacology; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism*; D005110:Extracellular Space / Q000187:drug effects / Q000378:metabolism; D005625:Frontal Lobe / Q000187:drug effects / Q000378:metabolism*; D006146:Guanidines / Q000494:pharmacology*; D007700:Kinetics; D008024:Ligands; D008297:Male; D017551:Microdialysis; D010423:Pentazocine / Q000494:pharmacology*; D010620:Phenazocine / Q000031:analogs & derivatives / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology*; D051381:Rats; D017208:Rats, Wistar; D017480:Receptors, sigma / Q000819:agonists*; D013997:Time Factors
chemical_list: D000927:Anticonvulsants; D014150:Antipsychotic Agents; D002227:Carbazoles; D006146:Guanidines; D008024:Ligands; D010880:Piperidines; D017480:Receptors, sigma; D015102:3,4-Dihydroxyphenylacetic Acid; C012134:SK&F 10047; C026539:preclamol; C034931:rimcazole; D010620:Phenazocine; C050232:1,3-ditolylguanidine; D010423:Pentazocine